Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Receivables - Other (2023 - 2025)

Historic Receivables - Other for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $5.0 million.

  • Monte Rosa Therapeutics' Receivables - Other rose 73445.38% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 73445.38%. This contributed to the annual value of $173000.0 for FY2024, which is 6574.26% down from last year.
  • Monte Rosa Therapeutics' Receivables - Other amounted to $5.0 million in Q3 2025, which was up 73445.38% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Receivables - Other peaked at $5.0 million during Q3 2025, and registered a low of $173000.0 during Q4 2024.
  • In the last 3 years, Monte Rosa Therapeutics' Receivables - Other had a median value of $842000.0 in 2024 and averaged $1.4 million.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Receivables - Other tumbled by 7230.41% in 2024 and then soared by 73445.38% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Receivables - Other stood at $505000.0 in 2023, then crashed by 65.74% to $173000.0 in 2024, then surged by 2769.94% to $5.0 million in 2025.
  • Its Receivables - Other stands at $5.0 million for Q3 2025, versus $2.4 million for Q2 2025 and $1.4 million for Q1 2025.